Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark
https://www.zacks.com/stock/news/2246922/abbott-s-abt-assert-iq-cardiac-monitor-receives-ce-mark?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246922
Mar 27, 2024 - Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
0
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
https://www.zacks.com/stock/news/2246920/here-s-why-you-should-buy-zimmer-biomet-zbh-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2246920
Mar 27, 2024 - Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.
0
Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now
https://www.zacks.com/stock/news/2246240/reasons-to-add-veeva-systems-veev-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2246240
Mar 26, 2024 - Veeva's strong product demand and strategic deals raise optimism about the stock.
0
GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite
https://www.zacks.com/stock/news/2246236/ge-healthcare-gehc-to-sell-ionic-s-fda-cleared-ncommand-lite?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246236
Mar 26, 2024 - GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.
0
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
https://www.zacks.com/stock/news/2245968/charles-river-crl-extends-gene-therapy-deal-with-nus-medicine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245968
Mar 26, 2024 - Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
0
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
https://www.zacks.com/stock/news/2245863/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2245863
Mar 26, 2024 - Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
0
Tandem Diabetes (TNDM) Gains From Innovation Amid Competition
https://www.zacks.com/stock/news/2245088/tandem-diabetes-tndm-gains-from-innovation-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2245088
Mar 22, 2024 - Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
0
3 Reasons Growth Investors Will Love Cardinal (CAH)
https://www.zacks.com/stock/news/2244383/3-reasons-growth-investors-will-love-cardinal-cah?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-2244383
Mar 21, 2024 - Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
0
Here's Why You Should Retain Nevro (NVRO) Stock for Now
https://www.zacks.com/stock/news/2244409/here-s-why-you-should-retain-nevro-nvro-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2244409
Mar 21, 2024 - Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
0
Reasons to Add Stryker (SYK) Stock in Your Portfolio Now
https://www.zacks.com/stock/news/2244193/reasons-to-add-stryker-syk-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2244193
Mar 21, 2024 - Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
0